# A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China

> **NCT07588880** · — · RECRUITING · sponsor: **Ipsen** · enrollment: 20 (estimated)

## Conditions studied

- Progressive Familial Intrahepatic Cholestasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07588880
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-16
- **Primary completion:** 2031-04-30
- **Final completion:** 2031-04-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07588880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07588880, "A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07588880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*